Discouraging news for high-dose chemotherapy in high-risk breast cancer.
Pusztai
L
L
Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030-4095, USA.
Hortobagyi
G N
GN
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D009367:Neoplasm Staging; D012074:Remission Induction; D012307:Risk Factors; D015996:Survival Rate
D000970:Antineoplastic Agents